期刊文献+

乳腺癌HER-2基因扩增和蛋白表达与ER、PR的关系及临床意义

在线阅读 下载PDF
导出
摘要 目的探讨HER-2基因及其蛋白在乳腺癌中扩增及表达状况,并研究其与ER、PR的相关性。方法用FISH技术和IHC技术检测51例乳腺癌新鲜标本中的HER-2基因的扩增及蛋白表达情况,并检测ER、PR进行对比分析。结果51例中10例HER-2蛋白表达强阳性(+++),6例阳性(++),2例弱阳性(+),33例阴性,其中基因过表达率(IHC检测++/+++)为31.4%;FISH检测中基因扩增14例,37例无扩增,扩增率为27.5%。IHC(++/+++)与FISH检测符合率87.5%(P〈0.05),ER、PR表达情况与HER-2基因及蛋白扩增呈负相关,ER和PR均为阴性的HER-2基因扩增率及蛋白表达率明显高于ER和(或)PR阳性的患者(IHC50%与24.3%,P〈0.05;FISH42.9%与19.4%,P〈0.05)。结论HER-2的扩增和蛋白过度表达提示乳腺癌预后不良,HER-2与ER、PR在乳腺癌的治疗中起重要作用,IHC可以作为检测HER-2基因状态的首选方法,但对于HER-2(++)需要进一步进行FISH检测。 Objective To study the amplification and expression of HER -2 gene and proteinum in breast cancer and to investigate the relationship between HER - 2 and proteinum and ER, PR. Method Apply fluorescence in situ hybridization and immunohistochemistry method to detect the amplification and expression of HER - 2 gene and proteinum and the expression of ER, PR in 51 case of breast cancer. All analysis were carried out using SPSS software. Results HER - 2 overexpression was 16 (31.4%) ,with( + + + ) 10 cases and ( + + ) 6 cases, There are 14 cases to find HER -2 gene amplification,the positive rate was 27. 5 % , the coincidence of HER -2 overexpression and HER -2 gene amplification was 87.5% (P 〈0. 05 ) , the expression of HER -2 had negative correlation with the expression ER ,PR, HER- 2 gene and proteinum positive expression was significant higher in PR and ER negative group than in PR and (or) ER positive group ( IHC 50% VS24. 3% ,P 〈0. 05, FISH 42.9% VS19.4% ,P 〈 0. 05 ). Conclusion The amplification and overexpression of HER - 2 gene and proteinum predict unfavourable prognosis in breast cancer. ER, PR and HER -2 play important roles on the occurrence and development in breast cancer. IHC can be used as a preferred method for detecting HER -2 gene, but for HER -2 ( + + ), further FISH test is needed.
出处 《浙江临床医学》 2009年第8期787-790,共4页 Zhejiang Clinical Medical Journal
关键词 HER-2癌基因 荧光原位杂交 免疫组化 乳腺癌 HER - 2 gene Fluorescence in situ hybridization Immunohistochemistry Breast cancer
  • 相关文献

参考文献11

  • 1Press MF,Slamon DJ,Flom KJ, et al. Evaluation of HER-2/neu gene amplification and overexpression. J Clin Oncol, 2002,20 : 3095 - 3105.
  • 2Ross JS, Gray GS. Targeted the rapy for cancer the HER - 2/neu and Herceptin story. Clin Leadersh Manag Rev,2003 ,17 :333 - 340.
  • 3Nabhohz JM, Slamon D. New adjuvant strategies for breast cancer: meeting the challenge of integrating chemotherapy and trastuzumab (Hereceptin). Semin Oncol,2001,28 ( 1 Suppl 3 ) : 1 - 12.
  • 4Slamon D, Clark G, Wong s. et al. Human breast cancer correlation of relapse and survival with amplification of the HER - 2/nen oncogene. Science, 1987,235 (4875) : 177 - 182.
  • 5Chorn N. Accurate identificarion of HER -2/nen positive patients is essential for superior outcomes with trastuzumab therapy. Oncol Nurs Forum,2006,33:265 - 272.
  • 6Watters AD,. Going JJ, Cooke TG, et al. Chromosome 17aneusomy is associated with poor prognostic factors in invasive breast carcinomal. breast Cancer Res Treat,2003,77 (2) : 109 - 114.
  • 7Thomson TA, Hayes MM, Spinelli JJ, et al. Her- 2/neu in breast cancer interobserver variability and performance sf immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization. Mod Pathol,2001,14 ( 11 ) : 1079 - 1076.
  • 8邱晓光,许岩丽,谷俊霞,郭丽霞,杨晓荣.c-erbB-2在不同乳腺病变组织中的表达及其临床意义的研究[J].肿瘤防治杂志,2001,8(3):239-240. 被引量:7
  • 9Meada S, Walatari M, Nagayama K, et al. Immunohistochemical analysis of overexpression of C - erbB - 2 protein in node - positive breast carcinoma. Nippon Geka Gakkai Zasshi,1993,94(1) :86.
  • 10Scorilas A, Yotis J, Stravolemos K, et al. C - erbB - 2 overexpression may be used as an independent prognostic factor for breast cancer pantients. Antieaneer Res, 1995,15 (4) : 1543.

二级参考文献2

共引文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部